Paul R Conkling MD

Oncology•Norfolk, VA

Physician

Join to View Full Profile

5900 Lake Wright DrNorfolk, VA 23502
Phone+1 757-466-8683
Fax+1 757-213-5846

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1985 - 1988
Duke University HospitalResidency, Internal Medicine, 1982 - 1985
Ohio State University College of MedicineClass of 1982

Certifications & Licensure

NC State Medical License 1984 - 2026
VA State Medical License 1988 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
COMPLETED
PHASE3
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
ACTIVE_NOT_RECRUITING
PHASE2
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors Start of enrollment: 2017 Dec 06
COMPLETED
PHASE1, PHASE2
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Start of enrollment: 2018 Oct 15
Completed
Phase 1
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Start of enrollment: 2019 Apr 01
COMPLETED
PHASE1
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Start of enrollment: 2019 Dec 10
ACTIVE_NOT_RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

11 citations
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage sm...
Chao Li, Lowell L. Hart, Taofeek K. Owonikoko, Raid Aljumaily, Caio Max Sao Pedro Rocha Lima
Cancer Chemotherapy and Pharmacology. 2021-02-17
45 citations
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly
Clinical Cancer Research. 2021-02-10
60 citations
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards
Journal of Clinical Oncology. 2021-01-29